OMass Therapeutics, a biotechnology company focused on small molecule therapeutics against highly validated target ecosystems, announced an oversubscribed Series C financing round of US$310 million, equivalent to £230 million. The financing was co-led by new investors Bain Capital Life Sciences, Forbion, and Novo Holdings. The proceeds will advance the company's lead program OMS1620 through Phase 2 development and generate early clinical data for a potential first-in-class SLC15A4 inhibitor.
Funding Details and Investor Syndicate
The Series C round was co-led by new investors Bain Capital Life Sciences, Forbion, and Novo Holdings, with additional participation from Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences. Existing investors Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and University of Oxford also participated in the round. The oversubscribed financing reflects strong demand from a top-tier international investor syndicate.
Clinical Pipeline and Strategic Focus
OMS1620 is designed as a potential best-in-class MC2 receptor antagonist for congenital adrenal hyperplasia, or CAH, and ACTH-dependent Cushing's syndrome. The candidate has been engineered to increase receptor residency time and maintain activity in the presence of rising endogenous ACTH levels. This mechanism may allow more patients with CAH to achieve androgen normalization while receiving physiologic doses of glucocorticoids.
The financing will also support OMass' earlier-stage pipeline, including generation of initial clinical data for a potential first-in-class SLC15A4 inhibitor. This program is being developed for lupus and other diseases associated with interferon overproduction and pathogenic B-cell activation. It represents a second internally discovered candidate poised to enter the clinic after OMS1620.
Investor Perspectives
Evan Greif, Principal at Bain Capital Life Sciences, said OMass leverages an experienced team and a clear vision for building a leading therapeutics company that translates complex biology into differentiated medicines. He noted that the company is executing against that vision by advancing OMS1620 and applying its proprietary discovery approach to build a broader pipeline across endocrinology and immunology. Greif added that he sees meaningful potential for OMS1620 to improve treatment for patients with CAH.
Audrey Cacaly, Principal at Forbion, said the financing has the potential to deliver clinical data for two differentiated programs, OMS1620 and the SLC15A4 inhibitor. She described the pipeline as built entirely through internal discovery, underscoring the productivity and breadth of OMass' platform. Cacaly added that the programs could generate meaningful new medicines across endocrine and immunologic diseases.
Leadership and Board Updates
Ros Deegan, Chief Executive Officer of OMass Therapeutics, said the financing arrives at an exciting point in the company's evolution as OMS1620 moves into the clinic. She noted that the team has demonstrated an ability to discover and deliver first- and best-in-class programs in endocrinology and immunology. Deegan added that the backing of new and existing investors provides the resources to translate progress into a portfolio of clinically differentiated medicines for patients.
In conjunction with the financing, Evan Greif of Bain Capital Life Sciences and Audrey Cacaly of Forbion will join the company's board of directors. Max Klement of Novo Holdings and Ali Jazayeri of SV Health Investors will receive board observer seats. The investor representatives expressed confidence in OMass' proprietary discovery approach and its ability to address significant unmet patient needs.
OMass Therapeutics is headquartered in Oxford, United Kingdom, and was founded as a spin-out from Professor Dame Carol Robinson's lab at the University of Oxford. Its proprietary OdyssION drug discovery platform combines next-generation native mass spectrometry, novel biochemistry techniques, and custom chemistry to interrogate drug targets within their native ecosystems. With the Series C financing, the company is positioned to advance a pipeline of first- and best-in-class programs across endocrinology and immunology.